Pembrolizumab as consolidation strategy in patients with multiple myeloma
PD1 expression in CD4 and CD8 T cells is increased after treatment in multiple myeloma patients with persistent disease. The GEM-Pembresid trial analyzed the efficacy and safety of pembrolizumab as consolidation in patients achieving at least very good partial response but with persistent measurable...
| Autores: | , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2020 |
| País: | España |
| Institución: | Universitat Autònoma de Barcelona |
| Repositorio: | Dipòsit Digital de Documents de la UAB |
| Idioma: | inglés |
| OAI Identifier: | oai:ddd.uab.cat:236711 |
| Acceso en línea: | https://ddd.uab.cat/record/236711 https://dx.doi.org/urn:doi:10.3390/cancers12123615 |
| Access Level: | acceso abierto |
| Palabra clave: | Consolidation Immunotherapy Myeloma Pembrolizumab |
| id |
ES_7d9a04e7d8dafa0daafcfb32b468b29e |
|---|---|
| oai_identifier_str |
oai:ddd.uab.cat:236711 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Pembrolizumab as consolidation strategy in patients with multiple myelomaResults of the GEM-pembresid clinical trialPuig, Noemí|||0000-0001-7535-3861Corchete Sánchez, Luis Antonio|||0000-0003-4577-8599Pérez-Morán, J. J.Dávila, J.Paíno, T.de la Rubia, Javier|||0000-0002-8354-768XOriol, Albert|||0000-0001-6804-2221Martín Sánchez, Jesús|||0000-0003-4250-4824De Arriba, Felipe|||0000-0002-4451-1318Bladé Creixenti, Juan|||0000-0002-4563-3405Blanchard, María JesúsGonzález-Calle, Verónica|||0000-0002-5493-6707García-Sanz, Ramón|||0000-0003-4120-2787Paiva, Bruno|||0000-0003-1977-3815Lahuerta, J. J.|||0000-0002-3393-9570San Miguel, Jesús|||0000-0002-9183-4857Mateos, M. V.|||0000-0003-2390-1218Ocio, Enrique M.|||0000-0002-5765-0085ConsolidationImmunotherapyMyelomaPembrolizumabPD1 expression in CD4 and CD8 T cells is increased after treatment in multiple myeloma patients with persistent disease. The GEM-Pembresid trial analyzed the efficacy and safety of pembrolizumab as consolidation in patients achieving at least very good partial response but with persistent measurable disease after first-or second-line treatment. Moreover, the characteristics of the immune system were investigated to identify potential biomarkers of response to pembrolizumab. One out of the 17 evaluable patients showed a decrease in the amount of M-protein, although a potential late effect of high-dose melphalan could not be ruled out. Fourteen adverse events were considered related to pembrolizumab, two of which (G3 diarrhea and G2 pneumonitis) prompted treatment discontinuation and all resolving without sequelae. Interestingly, pembrolizumab induced a decrease in the percentage of NK cells at cycle 3, due to the reduction of the circulating and adaptive subsets (0.615 vs. 0.43, p = 0.007; 1.12 vs. 0.86, p = 0.02). In the early progressors, a significantly lower expression of PD1 in CD8 effector memory T cells (MFI 1327 vs. 926, p = 0.03) was observed. In conclusion, pembrolizumab used as consolidation monotherapy shows an acceptable toxicity profile but did not improve responses in this MM patient population. The trial was registered at clinicaltrials.gov with identifier NCT02636010 and with EUDRACT number 2015-003359-23.Universitat Autònoma de Barcelona 22020-01-0120202020-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/236711https://dx.doi.org/urn:doi:10.3390/cancers12123615reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2367112026-06-06T12:50:31Z |
| dc.title.none.fl_str_mv |
Pembrolizumab as consolidation strategy in patients with multiple myeloma Results of the GEM-pembresid clinical trial |
| title |
Pembrolizumab as consolidation strategy in patients with multiple myeloma |
| spellingShingle |
Pembrolizumab as consolidation strategy in patients with multiple myeloma Puig, Noemí|||0000-0001-7535-3861 Consolidation Immunotherapy Myeloma Pembrolizumab |
| title_short |
Pembrolizumab as consolidation strategy in patients with multiple myeloma |
| title_full |
Pembrolizumab as consolidation strategy in patients with multiple myeloma |
| title_fullStr |
Pembrolizumab as consolidation strategy in patients with multiple myeloma |
| title_full_unstemmed |
Pembrolizumab as consolidation strategy in patients with multiple myeloma |
| title_sort |
Pembrolizumab as consolidation strategy in patients with multiple myeloma |
| dc.creator.none.fl_str_mv |
Puig, Noemí|||0000-0001-7535-3861 Corchete Sánchez, Luis Antonio|||0000-0003-4577-8599 Pérez-Morán, J. J. Dávila, J. Paíno, T. de la Rubia, Javier|||0000-0002-8354-768X Oriol, Albert|||0000-0001-6804-2221 Martín Sánchez, Jesús|||0000-0003-4250-4824 De Arriba, Felipe|||0000-0002-4451-1318 Bladé Creixenti, Juan|||0000-0002-4563-3405 Blanchard, María Jesús González-Calle, Verónica|||0000-0002-5493-6707 García-Sanz, Ramón|||0000-0003-4120-2787 Paiva, Bruno|||0000-0003-1977-3815 Lahuerta, J. J.|||0000-0002-3393-9570 San Miguel, Jesús|||0000-0002-9183-4857 Mateos, M. V.|||0000-0003-2390-1218 Ocio, Enrique M.|||0000-0002-5765-0085 |
| author |
Puig, Noemí|||0000-0001-7535-3861 |
| author_facet |
Puig, Noemí|||0000-0001-7535-3861 Corchete Sánchez, Luis Antonio|||0000-0003-4577-8599 Pérez-Morán, J. J. Dávila, J. Paíno, T. de la Rubia, Javier|||0000-0002-8354-768X Oriol, Albert|||0000-0001-6804-2221 Martín Sánchez, Jesús|||0000-0003-4250-4824 De Arriba, Felipe|||0000-0002-4451-1318 Bladé Creixenti, Juan|||0000-0002-4563-3405 Blanchard, María Jesús González-Calle, Verónica|||0000-0002-5493-6707 García-Sanz, Ramón|||0000-0003-4120-2787 Paiva, Bruno|||0000-0003-1977-3815 Lahuerta, J. J.|||0000-0002-3393-9570 San Miguel, Jesús|||0000-0002-9183-4857 Mateos, M. V.|||0000-0003-2390-1218 Ocio, Enrique M.|||0000-0002-5765-0085 |
| author_role |
author |
| author2 |
Corchete Sánchez, Luis Antonio|||0000-0003-4577-8599 Pérez-Morán, J. J. Dávila, J. Paíno, T. de la Rubia, Javier|||0000-0002-8354-768X Oriol, Albert|||0000-0001-6804-2221 Martín Sánchez, Jesús|||0000-0003-4250-4824 De Arriba, Felipe|||0000-0002-4451-1318 Bladé Creixenti, Juan|||0000-0002-4563-3405 Blanchard, María Jesús González-Calle, Verónica|||0000-0002-5493-6707 García-Sanz, Ramón|||0000-0003-4120-2787 Paiva, Bruno|||0000-0003-1977-3815 Lahuerta, J. J.|||0000-0002-3393-9570 San Miguel, Jesús|||0000-0002-9183-4857 Mateos, M. V.|||0000-0003-2390-1218 Ocio, Enrique M.|||0000-0002-5765-0085 |
| author2_role |
author author author author author author author author author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
Universitat Autònoma de Barcelona |
| dc.subject.none.fl_str_mv |
Consolidation Immunotherapy Myeloma Pembrolizumab |
| topic |
Consolidation Immunotherapy Myeloma Pembrolizumab |
| description |
PD1 expression in CD4 and CD8 T cells is increased after treatment in multiple myeloma patients with persistent disease. The GEM-Pembresid trial analyzed the efficacy and safety of pembrolizumab as consolidation in patients achieving at least very good partial response but with persistent measurable disease after first-or second-line treatment. Moreover, the characteristics of the immune system were investigated to identify potential biomarkers of response to pembrolizumab. One out of the 17 evaluable patients showed a decrease in the amount of M-protein, although a potential late effect of high-dose melphalan could not be ruled out. Fourteen adverse events were considered related to pembrolizumab, two of which (G3 diarrhea and G2 pneumonitis) prompted treatment discontinuation and all resolving without sequelae. Interestingly, pembrolizumab induced a decrease in the percentage of NK cells at cycle 3, due to the reduction of the circulating and adaptive subsets (0.615 vs. 0.43, p = 0.007; 1.12 vs. 0.86, p = 0.02). In the early progressors, a significantly lower expression of PD1 in CD8 effector memory T cells (MFI 1327 vs. 926, p = 0.03) was observed. In conclusion, pembrolizumab used as consolidation monotherapy shows an acceptable toxicity profile but did not improve responses in this MM patient population. The trial was registered at clinicaltrials.gov with identifier NCT02636010 and with EUDRACT number 2015-003359-23. |
| publishDate |
2020 |
| dc.date.none.fl_str_mv |
2 2020-01-01 2020 2020-01-01 |
| dc.type.none.fl_str_mv |
Article http://purl.org/coar/resource_type/c_6501 VoR http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.openaire.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.none.fl_str_mv |
https://ddd.uab.cat/record/236711 https://dx.doi.org/urn:doi:10.3390/cancers12123615 |
| url |
https://ddd.uab.cat/record/236711 https://dx.doi.org/urn:doi:10.3390/cancers12123615 |
| dc.language.none.fl_str_mv |
Inglés eng |
| language_invalid_str_mv |
Inglés |
| language |
eng |
| dc.rights.none.fl_str_mv |
open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by/4.0/ |
| dc.rights.openaire.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by/4.0/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.source.none.fl_str_mv |
reponame:Dipòsit Digital de Documents de la UAB instname:Universitat Autònoma de Barcelona |
| instname_str |
Universitat Autònoma de Barcelona |
| reponame_str |
Dipòsit Digital de Documents de la UAB |
| collection |
Dipòsit Digital de Documents de la UAB |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869411675935866880 |
| score |
15,300724 |